Management of trigeminal neuralgia in a rat model using intranasal administration of Bulleyaconitine A
The study shows BAA's superior efficacy compared to carbamazepine, highlighting its potential as a TTX-selective sodium channel blocker for TN. Intranasal BAA administration offers a novel, non-invasive therapeutic option. Further research on dosage forms for clinical use, such as drug-encapsulating nanoparticles or vesicles for targeted delivery in neurological disorders, is warranted.
Authors
- Yujie Ma (ORCID: https://orcid.org/0000-0001-7758-2625)
- Haolin Wang (ORCID: https://orcid.org/0000-0002-1735-9525)
- Yingying Xue (ORCID: https://orcid.org/0000-0002-2703-3772)
- Lei Xia (ORCID: https://orcid.org/0000-0003-1105-2239)
- Hui Yi (ORCID: https://orcid.org/0009-0004-9555-3915)
- Shaozhen Hu
- Jun Zhong (ORCID: https://orcid.org/0000-0003-4349-2431)
- Shiting Li (ORCID: https://orcid.org/0000-0001-6106-8891)
- Zhengnan Huang
- Haihong Cheng
- Yao Ge
Institutions
- Shanghai Medical College of Fudan University (CN)
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Digital China Health (China) (CN)
- Digital Science (United States) (US)
Publication Details
- Journal
- Neurological Research
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1080/01616412.2025.2511085
- Primary Topic
- Trigeminal Neuralgia and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00